These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22932321)

  • 1. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis.
    Ding X; Andraca-Carrera E; Cooper C; Miele P; Kornegay C; Soukup M; Marcus KA
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):441-7. PubMed ID: 22932321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.
    Cruciani M; Zanichelli V; Serpelloni G; Bosco O; Malena M; Mazzi R; Mengoli C; Parisi SG; Moyle G
    AIDS; 2011 Oct; 25(16):1993-2004. PubMed ID: 21716077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
    Brothers CH; Hernandez JE; Cutrell AG; Curtis L; Ait-Khaled M; Bowlin SJ; Hughes SH; Yeo JM; Lapierre DH
    J Acquir Immune Defic Syndr; 2009 May; 51(1):20-8. PubMed ID: 19282778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
    Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
    Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir use and risk of recurrent myocardial infarction.
    Sabin CA; Ryom L; d'Arminio Monforte A; Hatleberg CI; Pradier C; El-Sadr W; Kirk O; Weber R; Phillips AN; Mocroft A; Bonnet F; Law M; de Wit S; Reiss P; Lundgren JD;
    AIDS; 2018 Jan; 32(1):79-88. PubMed ID: 29028664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
    Sabin CA; Reiss P; Ryom L; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; de Wit S; Smith C; Dabis F; d'Arminio Monforte A; El-Sadr W; Lundgren JD;
    BMC Med; 2016 Mar; 14():61. PubMed ID: 27036962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.
    Brouwer ES; Napravnik S; Eron JJ; Stalzer B; Floris-Moore M; Simpson RJ; Stürmer T
    Epidemiology; 2014 May; 25(3):406-17. PubMed ID: 24713880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abacavir and cardiovascular risk.
    Behrens GM; Reiss P
    Curr Opin Infect Dis; 2010 Feb; 23(1):9-14. PubMed ID: 19996748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.
    Elion RA; Althoff KN; Zhang J; Moore RD; Gange SJ; Kitahata MM; Crane HM; Drozd DR; Stein JH; Klein MB; Eron JJ; Silverberg MJ; Mathews WC; Justice AC; Sterling TR; Rabkin CS; Mayor AM; Klein DB; Horberg MA; Bosch RJ; Eyawo O; Palella FJ;
    J Acquir Immune Defic Syndr; 2018 May; 78(1):62-72. PubMed ID: 29419568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
    Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
    Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
    Sosa N; Hill-Zabala C; Dejesus E; Herrera G; Florance A; Watson M; Vavro C; Shaefer M
    J Acquir Immune Defic Syndr; 2005 Dec; 40(4):422-7. PubMed ID: 16280696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials.
    Nan C; Shaefer M; Urbaityte R; Oyee J; Hopking J; Ragone L; Perger T; Win B; Vangerow H; McCoig C; Vannappagari V
    Open Forum Infect Dis; 2018 May; 5(5):ofy086. PubMed ID: 29766019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
    AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients.
    Falcinelli E; Francisci D; Schiaroli E; Minuz P; Orsini S; Malincarne L; Sebastiano M; Mezzasoma AM; Pasticci MB; Guglielmini G; Baldelli F; Gresele P
    Int J Cardiol; 2018 Jul; 263():118-124. PubMed ID: 29685693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
    Kowalska JD; Kirk O; Mocroft A; Høj L; Friis-Møller N; Reiss P; Weller I; Lundgren JD
    HIV Med; 2010 Mar; 11(3):200-8. PubMed ID: 19863618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.